Dimerix Ltd has released a press release.
DMX-200 Competitive Position Further Enhanced
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- CLARITY 2.0 Study Progresses In Patients With COVID-19
- Appendix 4D and Interim Financial Report
- Dimerix Plans for Next Study in Diabetic Kidney Disease
- Second Study to Include DMX-200 in COVID-19 Patients
- ARDS in COVID-19 Patients Protocol Published
Later from Dimerix
- Clinical Study in Patients with COVID-19 Progresses
- Major Shareholder Loan for $5 Million
- COVID-19 Study Recruits Multiple Patients in Europe
- DMX-200 Remains Eligible for Accelerated Approval
- Dimerix Confirms Phase 3 FSGS Study Design With EMA
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix